News Briefs: CMS to Hire “Small Army” of Drug Pricing Staff

After Michelle McMurray-Heath, M.D., resigned from her position as president and CEO of the Biotechnology Innovation Organization, the major industry trade group said on Oct. 11 that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., agreed to serve in those roles on an interim basis while BIO searches for a permanent successor. Before her departure, McMurray-Heath was on leave following disagreements with some board members over whether BIO should engage on social issues not directly connected to health care policy, which the molecular immunologist opposed, The Wall Street Journal reported. Her exit also comes in the wake of Congress’ passage of major drug pricing reforms as part of the Inflation Reduction Act, representing a rare defeat for the powerful pharma lobby.

© 2023 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

pills-in-dollar-sign
September 28

Retail Prescription Drug Spending Growth May Slow Down in Next Decade

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
September 28

News Briefs: Independent Pharmacists Seek ‘Payback’ From PBMs in CVS Lawsuit

READ MORE
person-leaning-out-of-line
September 28

‘Transparency-Rx’ Execs Explain Why They’re Breaking Rank, Backing PBM Reform

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today